Human Trials For Vaccine May Start Within A Few Weeks, But Health Experts Warn Against Unrealistic Expectations
A vaccine for broad public use is still 12 to 18 months away. Anyone promising anything faster 鈥渨ill be cutting corners that would be detrimental," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. Meanwhile drugmakers are working non-stop to try to find a treatment for the illness.
Human trials for a potential vaccine to prevent COVID-19 could begin 鈥渨ithin a few weeks鈥 with a vaccine ready for public use within the next 12 to 18 months, a top U.S. health official said Thursday. 鈥淲e said ... that it would take two to three months to have it in the first human,鈥澛燚r. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases,聽told the House Oversight and Reform Committee on Thursday at a hearing聽on the nation鈥檚 preparedness for the outbreak. (Lovelace and Higgins-Dunn, 3/12)
Nothing can stop a global outbreak in its tracks better than a vaccine. Unfortunately, creating a vaccine capable of preventing the coronavirus that causes COVID-19 will probably take at least a year to 18 months, health officials say. 鈥淭hat is the time frame,鈥 Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told the House Oversight and Reform Committee this week. Anyone who says they can do it faster 鈥渨ill be cutting corners that would be detrimental.鈥 (Khan, 3/12)
Dozens of drugmakers are scrambling to develop vaccines that could prevent people from contracting the new coronavirus, or therapies to treat people infected with the respiratory disease it causes. Testing of several potential drugs and vaccines has already started, and more trials are in the works. Additional studies could follow if researchers find that products approved for other uses, or even ones they discarded, show promise in their labs tackling the virus. 鈥淵ou鈥檙e seeing the industry wheel into action,鈥 says Jeremy Levin, chairman of the Biotechnology Innovation Organization trade group and chief executive of Ovid Therapeutics Inc. (Hopkins, 3/12)